Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors

Figure 3

(a) The pooled HRs for overall survival (OS) by LMR at baseline stratified on tumor types (RCC, NSCLC, GC, and multiple); (b) whether monotherapy or combined therapy; (c) LMR cut-off (<2 and ≥2); (d) countries (western countries and eastern countries); (e) type of ICI agents (anti-PD-1 and anti-PD-L1); (f) funnel plot for the evaluation of publication bias considering the association between the LMR at baseline and OS (19 studies).

(a)

(b)

(c)

(d)

(e)

(f)